检测不同生物学行为肾癌内LVD和MVD的临床意义

目的探讨淋巴管和微血管在不同生物学行为肾细胞癌（RCC）组织内的密度及其临床应用价值。方法40例肾细胞癌按其不同的生物学行为特点分为长期生存组和肿瘤转移组。肿瘤组织切片分别以针对血管内皮生长因子受体-3（VEGFR-3）和淋巴内皮透明质酸受-体1（LYVE-1）的单克隆抗体实施免疫组化染色,并对瘤组织内微血管和淋巴管进行计数。结果VEGFR-3非特异地表达于微血管和淋巴管内皮细胞浆,而LYVE-1仅特异地表达于淋巴管内皮细胞浆中。转移组瘤内MVD显著高于长期生存组（P〈0.05）。LYVE-1在转移组中仅有3例瘤内显示阳性。结论MVD可作为判断RCC患者预后的可靠指标。RCC缺乏瘤内淋巴管形成。

The clinical value of LVD and MVD in renal cell carcinoma with different biological behaviour

Objective To determine the intratumoral lymphatic vessel density(LVD) and microvessel density(MVD) in renal cell carcinoma(RCC) with different biological behaviour.Methods Forty patients were divided into two groups(the long-surviral group and the metastasis group) by the characteristics of biological behaviour of the tumor.The patients' tumoral tissue sections were immunostained with monoclonal antibodies against vascular endothelial growth factor receptor 3(VEGFR-3) and lymphatic endothelial hyaluronan receptor 1(LYVE-1) respectively,and the intratumoral LVD and MD were quantified.Results VEGFR-3 was expressed in both lymphatic vessel endothelial and vessel endothelial cytoplasm,but LYVE-1 only in lymphatic vessel endothelial cytoplasm.The metastasis group had a higher expression level of MVD than the long-survival group(P<0.05),but only 3 patients' tissues in the matastasis group were positive to LYVE-1.Conclusion VEGFR-3 may be a reliable marker in evaluating prognosis of RCC.Intratumoral lymphangiogenesis is not found in RCC.